Updates made to the 2013 ACIP recommendations on seasonal influenza vaccines
WASHINGTON — The Centers for Disease Control and Prevention has announced recommendations of the Advisory Committee on Immunization Practices for the 2014-15 influenza season.
The report updates the 2013 recommendations by the Advisory Committee on Immunization Practices regarding use of seasonal influenza vaccines.
Updated information for the 2014–15 influenza season includes 1) antigenic composition of U.S. seasonal influenza vaccines; 2) vaccine dose considerations for children aged 6 months through 8 years; and 3) a preference for the use, when immediately available, of live attenuated influenza vaccine for healthy children aged 2 through 8 years, to be implemented as feasible for the 2014–15 season but not later than the 2015–16 season. Information regarding issues related to influenza vaccination not addressed in this report is available in the 2013 ACIP seasonal influenza recommendations.
Information in the report reflects discussions during public meetings of ACIP on Feb. 26 and June 25.
Click here to read the report.
Report: U.S. hospitals experience more than 60 Ebola scares
NEW YORK — Hospitals and state laboratories in the United States have processed more than 60 Ebola scares over the course of the last few weeks, according to a report from ABC News.
Hospitals in 27 states notified the Centers for Disease Control and Prevention of the illnesses, doing so to be cautious due to the ongoing outbreak in Guinea, Liberia and Sierra Leone. Of the 68 cases reported, 58 were false alarms; blood samples of the remaining cases were sent out for testing.
The CDC is urging healthcare providers to ask patients about travel history to help with identifying potential cases, ABC News reported. The total number of deaths from the outbreak totals 1,229, and 2,240 people have been infected since March.
Pharmasmart completes initial testing phase for screening unit
ROCHESTER, N.Y. — PharmaSmart's PS2000 (D)estination completed its first alpha test inside a regional grocer, the company announced. Preliminary survey results received from the patients testing the unit inside the pharmacy reported that ease of use, ease of use, multi-biometric features, patented cuff size, virtual pharmacist and interoperability with pharmacy systems as the product's best features.
The company also said that the pharmacy staff overseeing the testing provided excellent anecdotal feedback regarding clinical features and benefit to healthcare objectives of their patients at point of care.
The company is targeting commercialization in late 2014 or early 2015. The PS2000 (D)estination will be showcased in booth #1727 at NACDS TSE.